Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07193147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 28, 2025 (before its estimated July 14, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting Start date changed from estimate of Oct 13, 2025 to Oct 20, 2025 · Site contact updatedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 13, 2025 to Oct 20, 2025
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.
Trial Details
NCT Number NCT07193147
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Diabetes
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov